Cargando…
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Hemophilia A (coagulation factor VIII deficiency) is a debilitating genetic disorder that is primarily treated with intravenous replacement therapy. Despite a variety of factor VIII protein formulations available, the risk of developing anti-dug antibodies (“inhibitors”) remains. Overall, 20–30% of...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705551/ https://www.ncbi.nlm.nih.gov/pubmed/29225598 http://dx.doi.org/10.3389/fimmu.2017.01604 |